Donafenib Tosilate Application Scope

Donafenib Tosylate is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Donafenib Tosilate Characteristics

Ingredients: Donafenib Tosylate
Properties: Oral small molecule multikinase inhibitor targeting Raf kinases, VEGFR, PDGFR, and other receptor tyrosine kinases
Packaging Specification: 100 mg tablets; typically administered as 200 mg (2 tablets) twice daily
Storage: Store at room temperature, away from moisture and heat
Expiry Date: Refer to packaging for specific expiry date
Executive Standard: China National Medical Products Administration (NMPA) standards
Approval Number: Approved by NMPA in June 2021
Date of Revision: Refer to packaging for the latest revision date
Manufacturer:Suzhou Zelgen Biopharmaceutical Co., Ltd.

Guidelines for the Use of Donafenib Tosilate

Dosage and Administration:
- Recommended Dose: 200 mg (2 tablets) orally, twice daily
- Administration: Take with or without food
- Missed Dose: If a dose is missed, take it as soon as remembered unless it’s almost time for the next dose; do not double doses
Adverse Reactions:
- Common Adverse Reactions: Fatigue, diarrhea, hand-foot skin reaction (palmar-plantar erythrodysesthesia), hypertension, rash
- Serious Adverse Reactions: Hepatotoxicity, cardiac issues (e.g., myocardial infarction, heart failure), bleeding complications, gastrointestinal perforations
Contraindications:
- Absolute Contraindications: Severe liver impairment, known hypersensitivity to donafenib or any component of the formulation
- Relative Contraindications: Pregnancy, breastfeeding, pre-existing cardiovascular conditions
Precautions:
- Monitoring: Regular monitoring of liver enzymes, blood pressure, and cardiac function is essential
- Drug Interactions: Caution when used with other medications metabolized by CYP3A4 or those that affect P-glycoprotein (P-gp)

Donafenib Tosilate Interactions

CYP3A4 Substrates: Donafenib may increase the plasma concentrations of drugs metabolized by CYP3A4
P-glycoprotein Substrates: Donafenib may affect the absorption and elimination of P-glycoprotein substrates
Anticoagulants: Monitor closely when used with warfarin or other anticoagulants due to potential bleeding risks

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.